

25 July 2007

The Manager Companies
Australian Stock Exchange Limited
20 Bridge Street
SYDNEY NSW 2000

(1 page by email)

Dear Madam

HIV DRUG DATA PRESENTED AT INTERNATIONAL CONFERENCE

The Directors of Biotron Limited ('Biotron' or 'the Company') are pleased to advise that the Company is presenting the latest preclinical efficacy data for its HIV drug development program at the 2007 International AIDS Society (IAS 2007) meeting on HIV Pathogenesis, Treatment and Prevention.

The IAS 2007 conference, currently underway in Sydney, is a meeting of the world's leading HIV professionals, providing a platform to showcase leading research, development and best clinical practice in HIV medicine. Over 5,000 delegates from 133 countries are participating in IAS 2007, more than 3,100 original abstracts were submitted for consideration and 978 were accepted for oral or poster presentation.

Biotron's HIV program had two abstracts accepted for presentation at the meeting as oral and poster presentations.

Dr John Wilkinson, Biotron's senior virologist, is presenting the most recent preclinical antiviral efficacy data on BIT225, the Company's lead anti-HIV compound. This includes demonstration in an *in vitro* model system that BIT225 prevents spread of HIV in infected human macrophage cells, as well as stopping transmission of HIV from these reservoirs cells to CD4 T cells. In addition, data is presented demonstrating that BIT225 inhibits replication of HIV in chronically-infected macrophage cells. Macrophages represent a reservoir of HIV in infected individuals, continually producing virus which infects the body's T cells. Current therapies do not target this cell population.

"This conference is an excellent opportunity to present results of our HIV studies with BIT225 to an international audience," said Dr Wilkinson.

Biotron's HIV program has made significant progress in 2007 with the commencement earlier this year of a Phase I clinical trial of BIT225 following successful completion of a formal preclinical safety and toxicology program late in 2006. The Phase I trial is meeting all of the Company's expectations.

For further information, please contact Dr Michelle Miller, CEO, on (61-2) 92478212.

Yours faithfully



Peter J. Nightingale
Company Secretary

pjn3964